Serum Clusterin In Patients With Chronic HCV infection Related Cirrhosis | ||||
| Sohag Medical Journal | ||||
| Article 37, Volume 22, Issue 3, October 2018, Page 315-319 PDF (67.74 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/smj.2018.34972 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Elham Hamed1; Tamer Abdel-Latef2; Ahmed Mahmoud2; Katren Fahem1 | ||||
| 1Department of Clinical andChemical pathology, Sohag Faculty of Medicine, Sohag University. | ||||
| 2Department of Clinical and Chemical pathology, Sohag Faculty of Medicine, Sohag University. | ||||
| Abstract | ||||
| Cirrhosis is a condition in which the liver does not function properly due to long term damage. Typically, the disease comes on slowly over months or years. Cirrhosis is characterized by the replacement of normal liver tissue by scar tissue. Clusterin (apolipoprotein J) is a 75 - 80 kDa disulfide-linked heterodimeric protein associated with the clearance of cellular debris and apoptosis. Objective: We aimed to evaluate the diagnostic performance of serum CLU level in diagnosing chronic HCV infection-related cirrhosis, and comparing it to that of alpha fetoprotein (AFP). Methods: Case control study was carried out in the Clinical Pathology Department, Faculty of medicine, Sohag university hospital.Twenty cases of apparently healthy subjects and 20 cases of chronic HCV infection-related cirrhosis(CHC cases) were included in this study. Serum CLU concentration was determined using a quantitative sandwich enzyme immunoassay technique. Results: Serum clusterin level showed a significant decrease in the CHC group compared to the control group (88.3 ± 30.7 vs. 110.7 ± 30.1). Conclusion: CLU is decreased in the serum of patients with established CHC. | ||||
|
Supplementary Files
|
||||
| References | ||||
|
1 . Abubakar, I. I., Tillmann, T., & Banerjee, A. ,2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 385(9963), 117-171.
2. Chi, K.N., Siu, L.L., Hirte, H., Hotte, S.J., Knox, J., Kollmansberger, C., Gleave, M., Guns, E., Powers, J., Walsh, W. and Tu, D., 2008. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clinical Cancer Research, 14(3), pp.833-839.
3. Debruyne, E.N., Vanderschaeghe, D., Van Vlierberghe, H., Vanhecke, A., Callewaert, N. and Delanghe, J.R., 2010. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clinical chemistry, 56(5), pp.823-831.
4. Ehsani Ardakani, M. J., Safaei, A., Arefi Oskouie, A., Haghparast, H., Haghazali, M., Mohaghegh Shalmani, H., … Zali, M. R. , 2016. Evaluation of liver cirrhosis and hepatocellular carcinoma using Protein-Protein Interaction Networks. Gastroenterology and Hepatology From Bed to Bench, 9(Suppl1), S14–S22.
5. Gangadharan, B., Antrobus, R., Dwek, R. A., & Zitzmann, N. ,2007. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clinical chemistry, 53(10), 1792-1799.
6. Jung, G.S., Kim, M.K., Jung, Y.A., Kim, H.S., Park, I.S., Min, B.H., Lee, K.U., Kim, J.G., Park, K.G. and Lee, I.K., 2012. Clusterin attenuates the development of renal fibrosis. Journal of the American Society of Nephrology, 23(1), pp.73-85.
7.Koltai, T., 2014. Clusterin: a key player in cancer chemoresistance and its inhibition. OncoTargets and therapy, 7, p.447.
8 . Lin, C.C., Tsai, P., Sun, H.Y., Hsu, M.C., Lee, J.C., Wu, I.C., Tsao, C.W., Chang, T.T. and Young, K.C., 2014. Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production. Journal of hepatology, 61(5), pp.984-993.
-9. Malaguarnera, G., Giordano, M., Paladina, I., Berretta, M., Cappellani, A. and Malaguarnera, M., 2010. Serum markers of hepatocellular carcinoma. Digestive diseases and sciences, 55(10), pp.2744-2755.
10. Norouzinia, M., Asadzadeh, H., Shalmani, H.M., Al Dulaimi, D. and Zali, M.R., 2012. Clinical and histological indicators of proximal and distal gastric cancer in eight provinces of Iran. Asian Pacific Journal of Cancer Prevention, 13(11), pp.5677-5679
11. Sansanwal, P., Li, L. and Sarwal, M.M., 2015. Inhibition of intracellular clusterin attenuates cell death in nephropathic cystinosis. Journal of the American Society of Nephrology, 26(3), pp.612-625.
12 . Wang, Y., Liu, Y.H., Mai, S.J., He, L.J., Liao, Y.J., Deng, H.X., Guan, X.Y., Zeng, Y.X., Kung, H.F. and Xie, D., 2010. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. Journal of gastroenterology and hepatology, 25(6), pp.1123-1128.
| ||||
|
Statistics Article View: 181 PDF Download: 261 |
||||
